Free tool
Drug Trial Radar
Last checked: Nov 20, 2026Latest source record: Nov 20, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
46
Recruiting, any sponsor type, condition "psoriatic arthritis"
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed203
46 trials
Showing 1 to 25, recently updated first.
- Comparing the Extent to Which Apremilast is Made Available in the Body After Administration as an Extended-release or Immediate-release FormulationPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT07908641 · 114 participants (planned) · Start Nov 18, 2026 · Primary completion Jan 10, 2027
Drug: Apremilast XR; Apremilast IR · For: Psoriasis; Arthritis, Psoriatic; Oral Ulcer
Sites: Daytona Beach, Florida; Dallas, Texas
- Carotid Ultrasound-Based Strategy for Primary Prevention of Cardiovascular Events in Inflammatory Rheumatic Disease (PREVENER)Pivotal-lookingRecruiting
Instituto de Investigación Marqués de ValdecillaAcademic, hospital or other
NCT07611747 · 1,117 participants (planned) · Start Apr 22, 2026 · Primary completion Apr 22, 2031
Drug: High-intensity lipid-lowering therapy · For: Rheumatoid Arthritis (RA); Psoriatic Arthritis (PsA); Systemic Lupus Erythematosus (SLE) and 4 more
Sites: Elche, Spain; Orihuela, Spain; Sant Joan d'Alacant, Spain · 17 sites in all
South Valley UniversityAcademic, hospital or other
NCT07946497 · 105 participants (planned) · Start Oct 1, 2026 · Primary completion Oct 1, 2027
Drug: Methotrexate · For: Chronic Plaque Psoriasis; Psoriatic Arthritis
Sites: Qina, Egypt
National Cancer Institute (NCI)NIH
NCT03816345 · 300 participants (planned) · Start Jul 16, 2019 · Primary completion Mar 30, 2028
Drug: Cabozantinib; Fluoropyrimidine and 4 more · For: Autoimmune Disease; Crohn Disease; Dermatomyositis and 11 more
Sites: Birmingham, Alabama; Palo Alto, California; Sacramento, California · 52 sites in all
- Continuation Study of Zasocitinib in Adults With Psoriatic ArthritisPivotal-lookingRecruiting
TakedaTakeda (TAK)
NCT07286058 · 1,182 participants (planned) · Start Mar 11, 2026 · Primary completion Dec 18, 2029
Drug: Zasocitinib · For: Psoriatic Arthritis
Sites: Tucson, Arizona; Fountain Valley, California; La Mesa, California · 111 sites in all
- A Study to Assess the Efficacy, Safety and Tolerability of DDY391 in Participants With Moderate to Severe Psoriatic ArthritisPivotal-lookingRecruiting
Novartis PharmaceuticalsNovartis (NVS)
NCT07801495 · 220 participants (planned) · Start Oct 19, 2026 · Primary completion Dec 13, 2028
Drug: DDY391; Placebo · For: Moderate to Severe Psoriatic Arthritis
Sites: Huntington Beach, California; Duncansville, Pennsylvania; Philadelphia, Pennsylvania · 8 sites in all
- Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic ArthritisPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06865105 · 300 participants (planned) · Start Apr 11, 2025 · Primary completion Aug 2029
Drug: Lutikizumab; Risankizumab and 2 more · For: Psoriatic Arthritis
Sites: Huntington Beach, California; Avon Park, Florida; Clearwater, Florida · 41 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06751238 · 20 participants (planned) · Start Sep 24, 2025 · Primary completion Oct 31, 2029
Drug: Secukinumab · For: Juvenile Psoriatic Arthritis
Sites: Loma Linda, California; Gainesville, Florida; Chicago, Illinois · 11 sites in all
- A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in AdultsPivotal-lookingRecruiting
NCT07290036 · 392 participants (planned) · Start Dec 10, 2025 · Primary completion May 18, 2028
Drug: Bimekizumab regimen 1 iv; Bimekizumab regimen 2 iv and 1 more · For: Psoriatic Arthritis; Axial Spondyloarthritis
Sites: Peoria, Arizona; Apple Valley, California; Covina, California · 65 sites in all
Medical College of WisconsinAcademic, hospital or other
NCT07111494 · 22 participants (planned) · Start May 1, 2026 · Primary completion Oct 15, 2027
Drug: GLP-1 agonists · For: Psoriatic Arthritis (PsA)
Sites: Milwaukee, Wisconsin
- A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic ArthritisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT05767047 · 48 participants (planned) · Start Mar 23, 2023 · Primary completion Mar 17, 2036
Drug: Apremilast · For: Behçet's Disease; Juvenile Psoriatic Arthritis
Sites: Thessaloniki, Greece; Kfar Saba, Israel; Valencia, Spain · 7 sites in all
- A Study of Baricitinib in Participants From 1 Year to Less Than 18 Years Old With Juvenile Idiopathic ArthritisPivotal-lookingRecruiting
Eli Lilly and CompanyEli Lilly (LLY)
NCT03773965 · 190 participants (planned) · Start Apr 5, 2019 · Primary completion Jul 2031
Drug: Baricitinib · For: Juvenile Idiopathic Arthritis
Sites: Rosario, Argentina; SAN M. de Tucuman, Argentina; Melbourne, Australia · 77 sites in all
- A Long-term Extension (LTE) Study of Guselkumab in Pediatric ParticipantsPivotal-lookingRecruiting
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT06663332 · 196 participants (planned) · Start Oct 29, 2024 · Primary completion Dec 12, 2031
Drug: Guselkumab · For: Crohns Disease; Colitis, Ulcerative; Arthritis, Psoriatic and 1 more
Sites: Atlanta, Georgia; Indianapolis, Indiana; Cincinnati, Ohio · 53 sites in all
Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
NCT07654751 · 10 participants (planned) · Start Aug 7, 2026 · Primary completion Aug 31, 2027
Drug: Guselkumab · For: Psoriasis; Colitis, Ulcerative; Crohn Disease and 1 more
Sites: Chapel Hill, North Carolina
NCT06668181 · 40 participants (planned) · Start Mar 11, 2025 · Primary completion Apr 12, 2028
Drug: Bimekizumab · For: Enthesitis-related Arthritis; Juvenile Psoriatic Arthritis
Sites: Calgary, Canada; Montreal, Canada; Saskatoon, Canada · 23 sites in all
- Apremilast Pediatric Study in Children With Active Juvenile Psoriatic ArthritisPivotal-lookingRecruiting
AmgenAmgen (AMGN)
NCT04804553 · 60 participants (planned) · Start Mar 17, 2022 · Primary completion Mar 21, 2028
Drug: Apremilast; Placebo · For: Active Juvenile Psoriatic Arthritis
Sites: Ghent, Belgium; Liège, Belgium; Merksem, Belgium · 44 sites in all
- A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic ArthritisPivotal-lookingRecruiting
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT06869551 · 60 participants (planned) · Start Mar 13, 2025 · Primary completion Mar 6, 2030
Drug: Deucravacitinib · For: Juvenile Psoriatic Arthritis
Sites: Lancaster, California; Chicago, Illinois; Indianapolis, Indiana · 48 sites in all
NCT06888193 · 20 participants (planned) · Start Nov 5, 2025 · Primary completion Dec 31, 2027
Drug: Bimekizumab · For: Moderate to Severe Plaque Psoriasis; Psoriatic Arthritis; Axial Spondyloarthritis and 1 more
Sites: Santa Monica, California; South Miami, Florida; Boston, Massachusetts · 14 sites in all
- A Clinical Trial of TQH3906 Capsules in the Treatment of Active Psoriatic ArthritisPivotal-lookingRecruiting
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Industry
NCT07406035 · 156 participants (planned) · Start Jul 16, 2026 · Primary completion Aug 2027
Drug: TQH3906 Capsule; TQH3906 Placebo Capsule and 1 more · For: Psoriatic Arthritis
Sites: Bozhou, China; Beijing, China; Chongqing, China · 44 sites in all
- A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or AdalimumabPivotal-lookingRecruiting
AbbVieAbbVie (ABBV)
NCT06100744 · 40 participants (planned) · Start Jul 8, 2024 · Primary completion Sep 2026
Drug: Adalimumab; Risankizumab · For: Juvenile Psoriatic Arthritis
Sites: Little Rock, Arkansas; Washington D.C., District of Columbia; Hollywood, Florida · 34 sites in all
- Deucravacitinib-TNFi Combination Therapy for Difficult-to-Control Psoriatic DiseasePivotal-lookingRecruiting
University of Texas Southwestern Medical CenterAcademic, hospital or other
NCT07280702 · 128 participants (planned) · Start Jun 16, 2026 · Primary completion Dec 15, 2027
Drug: Deucravacitinib; Placebo · For: Psoriatic Arthritis (PsA)
Sites: Dallas, Texas
Johnson & Johnson Private LimitedJohnson & Johnson (Janssen) (JNJ)
NCT07141004 · 100 participants (planned) · Start Aug 12, 2025 · Primary completion Jun 5, 2027
Drug: Guselkumab · For: Arthritis, Psoriatic
Sites: Ahmedabad, India; Chandigarh, India; Chennai, India · 11 sites in all
PfizerPfizer (PFE)
NCT05754710 · 10 participants (planned) · Start Apr 12, 2024 · Primary completion Sep 30, 2026
Drug: Xeljanz · For: Psoriatic Arthritis, Juvenile; Polyarticular Juvenile Idiopathic Arthritis
Sites: Seoul, South Korea
Centre Hospitalier Universitaire, AmiensAcademic, hospital or other
NCT07718815 · 658 participants (planned) · Start May 6, 2025 · Primary completion Sep 2026
Drug: blood test · For: Psoriatic Arthritis; HLA b Leader; HLA B27
Sites: Amiens, France
University of Sao Paulo General HospitalAcademic, hospital or other
NCT07087912 · 477 participants (planned) · Start Mar 16, 2026 · Primary completion Dec 30, 2027
Drug: Dengue 1,2,3,4 (attenuated) vaccine · For: Rheumatoid Arthritis (RA); Juvenile Idiopathic Arthritis (JIA); Systemic Lupus Erythematosus (SLE) and 9 more
Sites: São Paulo, Brazil · 2 sites in all
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.